Published in Proc Natl Acad Sci U S A on October 26, 1999
Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol (2009) 6.62
A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J (2006) 4.95
Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J (2000) 4.85
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A (2000) 4.41
Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev (2000) 4.24
Sequence and structural analysis of BTB domain proteins. Genome Biol (2005) 3.88
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev (2001) 3.67
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res (2006) 3.04
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev (1999) 2.78
Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol (2002) 2.31
Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast. EMBO J (2000) 2.27
The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol (2001) 2.26
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol (2005) 2.25
Gp78 cooperates with RMA1 in endoplasmic reticulum-associated degradation of CFTRDeltaF508. Mol Biol Cell (2008) 2.14
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer (2011) 2.06
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
HECT and RING finger families of E3 ubiquitin ligases at a glance. J Cell Sci (2012) 1.95
Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal (2010) 1.85
Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem J (2004) 1.83
Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A (2000) 1.82
Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol Biol Cell (2001) 1.69
Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol (2002) 1.67
Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol (2007) 1.67
The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol Cell Biol (2003) 1.62
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol (2007) 1.62
The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ (2008) 1.61
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.59
Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A (2006) 1.57
von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest (2007) 1.56
CUL-4A is critical for early embryonic development. Mol Cell Biol (2002) 1.51
Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol (2004) 1.48
Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. Mol Cell Biol (2004) 1.48
The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest (2010) 1.46
Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase. Proc Natl Acad Sci U S A (2002) 1.43
HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B (2015) 1.40
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer (2004) 1.39
Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol (2002) 1.38
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A (2000) 1.36
SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol (2005) 1.36
The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol (2005) 1.34
VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol (2001) 1.31
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep (2009) 1.25
Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci (2008) 1.24
The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J (2003) 1.24
Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol (2015) 1.21
Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc Natl Acad Sci U S A (2008) 1.20
E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol (2006) 1.19
Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One (2010) 1.17
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol (2002) 1.16
VHL: a very hip ligase. Proc Natl Acad Sci U S A (1999) 1.14
Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem (2006) 1.13
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J (2003) 1.12
Diversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system. Microbiol Mol Biol Rev (2012) 1.11
Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex. Neoplasia (2006) 1.08
Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res (2010) 1.06
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int (2009) 1.03
Aberrant expression of microRNAs in gastric cancer and biological significance of miR-574-3p. Int Immunopharmacol (2012) 1.03
Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proc Natl Acad Sci U S A (2003) 1.03
The E4orf6/E1B55K E3 ubiquitin ligase complexes of human adenoviruses exhibit heterogeneity in composition and substrate specificity. J Virol (2010) 1.03
Targeted disruption of Drosophila Roc1b reveals functional differences in the Roc subunit of Cullin-dependent E3 ubiquitin ligases. Mol Biol Cell (2004) 1.01
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther (2008) 1.00
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues. Mol Cancer (2003) 0.98
The von Hippel-Lindau gene: turning discovery into therapy. Cancer (2008) 0.97
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene (2009) 0.96
The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des (2009) 0.93
Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. J Biol Chem (2011) 0.93
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma. J Biol Chem (2010) 0.91
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther (2010) 0.91
Identifying determinants of cullin binding specificity among the three functionally different Drosophila melanogaster Roc proteins via domain swapping. PLoS One (2008) 0.90
TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res (2013) 0.90
Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res (2008) 0.89
The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene (2009) 0.88
Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins. J Virol (2014) 0.87
Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer (2009) 0.87
HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation. Cancer Cell Int (2007) 0.87
Combination of multiple alignment analysis and surface mapping paves a way for a detailed pathway reconstruction--the case of VHL (von Hippel-Lindau) protein and angiogenesis regulatory pathway. Protein Sci (2004) 0.86
Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. Biochem J (2015) 0.85
Mitochondrial regulation of cell survival and death during low-oxygen conditions. Antioxid Redox Signal (2009) 0.85
Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. Expert Opin Drug Discov (2008) 0.85
Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. J Cell Mol Med (2009) 0.82
Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. Cancer Res (2014) 0.81
PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Br J Cancer (2013) 0.81
Congenital erythrocytosis associated with gain-of-function HIF2A gene mutations and erythropoietin levels in the normal range. Haematologica (2013) 0.81
Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem (2007) 0.80
Microtubular stability affects pVHL-mediated regulation of HIF-1alpha via the p38/MAPK pathway in hypoxic cardiomyocytes. PLoS One (2012) 0.80
Elongin C is a mediator of Notch4 activity in human renal tubule cells. Biochim Biophys Acta (2011) 0.80
Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor. Mol Cell Biol (2007) 0.80
Maize Elongin C interacts with the viral genome-linked protein, VPg, of Sugarcane mosaic virus and facilitates virus infection. New Phytol (2014) 0.80
VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Sci Rep (2016) 0.79
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid. Endocr Pathol (2000) 0.79
Erythropoietic agents and the elderly. Semin Hematol (2008) 0.78
Exposure to cigarette smoke induces overexpression of von Hippel-Lindau tumor suppressor in mouse skeletal muscle. Am J Physiol Lung Cell Mol Physiol (2012) 0.78
Increased Nek1 expression in renal cell carcinoma cells is associated with decreased sensitivity to DNA-damaging treatment. Oncotarget (2014) 0.78
pVHL mediates K63-linked ubiquitination of nCLU. PLoS One (2012) 0.78
Differential effects of HIF-α isoforms on apoptosis in renal carcinoma cell lines. Cancer Cell Int (2015) 0.77
E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis. BMC Cancer (2015) 0.77
The ubiquitin system. Annu Rev Biochem (1998) 43.36
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 12.41
Ubiquitin-dependent protein degradation. Annu Rev Genet (1996) 10.97
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
The ubiquitin-proteasome proteolytic pathway. Cell (1994) 9.75
Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature (1994) 9.30
A family of cytokine-inducible inhibitors of signalling. Nature (1997) 9.22
The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev (1999) 6.56
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
A new protein containing an SH2 domain that inhibits JAK kinases. Nature (1997) 6.28
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science (1999) 5.72
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis. Trends Genet (1998) 4.90
Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature (1998) 4.89
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science (1999) 4.65
ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell (1999) 4.53
Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A (1998) 4.38
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev (1998) 4.29
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev (1999) 4.17
cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell (1996) 4.11
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A (1999) 3.91
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The oncogenic activation of beta-catenin. Curr Opin Genet Dev (1999) 3.87
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell (1999) 3.58
A novel protein modification pathway related to the ubiquitin system. EMBO J (1998) 3.36
How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell (1999) 3.34
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
von Hippel-Lindau disease. Medicine (Baltimore) (1997) 2.89
A new NEDD8-ligating system for cullin-4A. Genes Dev (1998) 2.82
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Proteolysis and the G1-S transition: the SCF connection. Curr Opin Genet Dev (1998) 2.35
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res (1996) 2.10
The VHL tumour-suppressor gene paradigm. Trends Genet (1998) 1.94
Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc Natl Acad Sci U S A (1999) 1.78
Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem (1996) 1.43
Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci U S A (1999) 1.42
Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaBalpha. J Biol Chem (1999) 1.39
VHL: a very hip ligase. Proc Natl Acad Sci U S A (1999) 1.14
The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today (1999) 1.06
The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein. Biochim Biophys Acta (1998) 1.05
Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell (1989) 13.41
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway. Cell (1990) 9.19
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
The mammalian gene collection. Science (1999) 7.19
The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol (1995) 6.99
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science (1999) 6.38
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell (1991) 6.30
Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. Nature (1992) 6.11
Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: identification of a nonlysosomal acidic compartment. Proc Natl Acad Sci U S A (1982) 5.74
PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science (1994) 5.62
Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor. Proc Natl Acad Sci U S A (1990) 5.35
Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science (1988) 4.86
Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J (1995) 4.83
A systematic, high-resolution linkage of the cytogenetic and physical maps of the human genome. Nat Genet (2000) 4.78
Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci U S A (1983) 4.68
Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science (1999) 4.65
A permease-oxidase complex involved in high-affinity iron uptake in yeast. Science (1996) 4.60
Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell (1988) 4.42
Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A (2000) 4.41
A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell (1992) 4.39
Binding of a cytosolic protein to the iron-responsive element of human ferritin messenger RNA. Science (1988) 4.35
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev (1998) 4.29
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatomer protein beta-COP to Golgi membranes. Proc Natl Acad Sci U S A (1992) 4.22
Identification of the components of the murine T cell antigen receptor complex. Cell (1985) 4.20
Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science (1987) 4.20
Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae. Cell (1991) 4.17
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol (1998) 4.14
Dissociation of a 110-kD peripheral membrane protein from the Golgi apparatus is an early event in brefeldin A action. J Cell Biol (1990) 3.90
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport. Cell (1994) 3.88
Overexpression of wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlapping membrane compartments. J Cell Biol (1995) 3.82
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
General initiation factors for RNA polymerase II. Annu Rev Biochem (1993) 3.69
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev (2001) 3.67
The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. RNA (2001) 3.65
Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem (1983) 3.65
Failure to synthesize the T cell CD3-zeta chain: structure and function of a partial T cell receptor complex. Cell (1988) 3.59
Oxidation-reduction and the molecular mechanism of a regulatory RNA-protein interaction. Science (1989) 3.54
Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science (1995) 3.53
An RNA polymerase II elongation factor encoded by the human ELL gene. Science (1996) 3.46
Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer (2000) 3.46
Binding of ARF and beta-COP to Golgi membranes: possible regulation by a trimeric G protein. Science (1991) 3.33
Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell (1986) 3.30
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol (1998) 3.30
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
Membrane protein association by potential intramembrane charge pairs. Nature (1991) 3.27
Lipid domains in membranes. Evidence derived from structural perturbations induced by free fatty acids and lifetime heterogeneity analysis. J Biol Chem (1980) 3.20
Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci U S A (1998) 3.18
Escherichia coli FtsH is a membrane-bound, ATP-dependent protease which degrades the heat-shock transcription factor sigma 32. EMBO J (1995) 3.18
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol (1985) 3.18
The cancer genome anatomy project: building an annotated gene index. Trends Genet (2000) 3.02
Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation. Nature (1989) 3.02
NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J (2001) 2.94
A cis-acting element is necessary and sufficient for translational regulation of human ferritin expression in response to iron. Proc Natl Acad Sci U S A (1987) 2.89
Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature (1995) 2.87
Ferric reductase of Saccharomyces cerevisiae: molecular characterization, role in iron uptake, and transcriptional control by iron. Proc Natl Acad Sci U S A (1992) 2.87
Genetic evidence that ferric reductase is required for iron uptake in Saccharomyces cerevisiae. Mol Cell Biol (1990) 2.83
A cytosolic protein binds to structural elements within the iron regulatory region of the transferrin receptor mRNA. Proc Natl Acad Sci U S A (1989) 2.81
Control of elongation by RNA polymerase II. Trends Biochem Sci (2000) 2.79
The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev (1999) 2.78
AFT1: a mediator of iron regulated transcriptional control in Saccharomyces cerevisiae. EMBO J (1995) 2.76
Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3' UTR and does not involve poly(A) tail shortening. EMBO J (1994) 2.70
Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science (1992) 2.67
Pre-Golgi degradation of newly synthesized T-cell antigen receptor chains: intrinsic sensitivity and the role of subunit assembly. J Cell Biol (1989) 2.65
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Iron-regulated DNA binding by the AFT1 protein controls the iron regulon in yeast. EMBO J (1996) 2.62
New opportunities for uncovering the molecular basis of cancer. Nat Genet (1997) 2.61
Building a multichain receptor: synthesis, degradation, and assembly of the T-cell antigen receptor. Proc Natl Acad Sci U S A (1987) 2.58
Molecular cloning of the zeta chain of the T cell antigen receptor. Science (1988) 2.58
The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J Biol Chem (1994) 2.57
Iron regulation of transferrin receptor mRNA levels requires iron-responsive elements and a rapid turnover determinant in the 3' untranslated region of the mRNA. EMBO J (1989) 2.54
Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes. Proc Natl Acad Sci U S A (1982) 2.54
A DNA primase activity associated with DNA polymerase alpha from Drosophila melanogaster embryos. Proc Natl Acad Sci U S A (1982) 2.53
The Menkes/Wilson disease gene homologue in yeast provides copper to a ceruloplasmin-like oxidase required for iron uptake. Proc Natl Acad Sci U S A (1995) 2.50
T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substrates. J Biol Chem (1989) 2.50
Colocalized transmembrane determinants for ER degradation and subunit assembly explain the intracellular fate of TCR chains. Cell (1990) 2.49
Activation of the translational suppressor 4E-BP1 following infection with encephalomyocarditis virus and poliovirus. Proc Natl Acad Sci U S A (1996) 2.47